Amarin Corporation plc (AMRN)

Market Cap	243.12M -40.1%
Revenue (ttm)	186.23M -15.1%
Net Income	-27.12M
EPS	-1.30
Shares Out	21.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,944
Open	11.60
Previous Close	11.48
Day's Range	11.46 - 11.67
52-Week Range	11.25 - 20.90
Beta	0.77
Analysts	Strong Sell
Price Target	12.50 (+8.6%)
Earnings Date	Oct 28, 2026

About AMRN

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaborat...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Apr 1, 1993
• Employees: 80
• Stock Exchange: Nasdaq
• Ticker Symbol: AMRN
• Website: https://www.amarincorp.com

Financial Performance

In 2025, Amarin Corporation's revenue was $213.65 million, a decrease of -6.55% compared to the previous year's $228.61 million. Losses were -$38.80 million, -52.79% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for AMRN stock is "Strong Sell." The 12-month stock price target is $12.5, which is an increase of 8.60% from the latest price.

Price Target

$12.5

(8.60% upside)

Analyst Consensus: Strong Sell

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 21, 2026

Data Sources Report a data error